Skip to main content

Table 3 Correlation of CLEC3B expression and prognosis in lung cancer with clinicopathological factors by Kaplan-Meier plotter

From: CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment

Clinicopathological characteristics Overall survival (n = 1928) Progression-free survival (n = 982)
N HR (95% CI) p-value N HR (95% CI) p-value
Sex
 Female 715 0.64 (0.5–0.81) 0.00022 468 0.59 (0.44–0.80) 0.00051
 Male 1100 0.69 (0.59–0.81) 5.9e−06 514 0.62 (0.48–0.80) 0.00026
Stage
 1 577 0.58 (0.44–0.76) 5.85e−05 325 0.51 (0.33–0.81) 0.0033
 2 244 1.61 (1.06–2.45) 0.024 130 0.40 (0.20–0.81) 0.0089
 3 70 1.49 (0.83–2.70) 0.18 19 na na
 4 4 na na 0 na na
T stage
 1 437 0.64 (0.48–0.86) 0.0024 177 0.49 (0.29–0.84) 0.008
 2 589 0.66 (0.52–0.83) 0.00044 351 0.50 (0.34–0.74) 4e−04
 3 81 1.69 (1.03–2.78) 0.037 21 0.65 (0.24–1.80) 0.41
 4 46 0.50 (0.26–0.96) 0.033 7 na na
N stage
 0 781 0.69 (0.56–0.86) 0.00066 374 0.59 (0.43–0.82) 0.0013
 1 252 0.67 (0.48–0.92) 0.014 130 0.38 (0.21–0.67) 0.00051
 2 111 0.72 (0.45–1.14) 0.15 51 0.50 (0.25–1.00) 0.047
M stage
 0 681 0.61 (0.49–0.75) 2.3e−06 195 0.56 (0.33–0.94) 0.026
 1 10 na na 0 na na
Grade
 I 201 0.84 (0.58–1.21) 0.35 140 0.68 (0.42–1.10) 0.12
 II 310 0.63 (0.45–0.87) 0.0052 165 0.48 (0.30–0.77) 0.002
 III 77 0.47 (0.24–0.91) 0.022 51 1.47 (0.64–3.35) 0.36
Smoke
 Ever 820 0.76 (0.62–0.93) 0.0082 603 0.58 (0.44–0.75) 2.7e−05
 Never 205 0.41 (0.23–0.72) 0.0013 193 0.48 (0.29–0.79) 0.0032
  1. Values in italics indicate p < 0.05
  2. CI, confidence interval; HR, hazard ratio; na, not applicable